Skip to main content
Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc. — Investor Relations & Filings

Ticker · COCP ISIN · US19188J4094 LEI · 549300QCJ6RBUJKI7S66 US Manufacturing
Filings indexed 531 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US COCP

About Cocrystal Pharma, Inc.

https://www.cocrystalpharma.com/

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics for serious and chronic viral diseases. The company utilizes proprietary structure-based drug design technologies to create antiviral drugs that target the viral replication process. Its development pipeline includes programs targeting influenza, SARS-CoV-2 (COVID-19), norovirus, and hepatitis C. Key candidates in its pipeline include CC-42344, a PB2 inhibitor for influenza A in Phase 2 clinical trials, and CDI-988, an oral pan-viral protease inhibitor for norovirus and coronaviruses that has entered Phase 1 trials.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report
2026-05-15 English
S-3 - Cocrystal Pharma, Inc. (0001412486) (Filer)
Registration Form
2026-04-23 English
8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
Regulatory Filings
2026-04-02 English
10-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
Annual Report FY 2025
2026-03-31 English
8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
Regulatory Filings
2026-03-31 English
4 - COCRYSTAL PHARMA, INC. (0001412486) (Filer)
Director's Dealing
2026-02-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.